Primary plasma cell leukemia (pPCL) is a rare and highly aggressive plasma cell malignancy, often associated with complex ...

Singapore, Singapore, October 7th, 2025, ChainwirePendle Finance, the world’s biggest yield trading platform in ...

Pendle Finance, the world’s biggest yield trading platform in crypto, has recorded an astonishing infusion of $318 million in ...

Frankie, a playful baby dachshund just a few months old, is fighting through unimaginable odds after being hit by a car and ...

BioLife Plasma opened a new plasma center in Madison Jan. 30, their first to be open in the city and 14th open in the state, according to the Wisconsin State Journal. Plasma has been of particular ...

Andhra Pradesh Health Minister addresses blood donation challenges, emphasizes rational blood use to prevent shortages and ...

While total outward FDI dipped year-on-year, equity commitments tripled to $2.57 billion; Prime Focus, Intas, and Zydus among ...

Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, and Protalix BioTherapeutics, Inc.

The FDA has approved Kedrion Biopharma’s Qivigy, a 10% IV immunoglobulin therapy, for treating adults who have primary ...

Discover JECT's latest medical-grade, innovative treatments to transform the skin, from Aquagold to wrinkle reducers.

CSL Behring Canada Inc., a business unit of global biopharma leader CSL, today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public ...